U.K. Provides £50 Million Extra For Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive SummaryExtra funds made available in the U.K. for anti-cancers turned down by NICE, with a £200 million fund to be set up next year.
You may also be interested in...
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.
Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.
Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.